U.S. markets open in 5 hours 53 minutes

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0500-0.1000 (-4.65%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close2.1500
Open2.1300
Bid0.0000 x 4000
Ask0.0000 x 1200
Day's Range2.0400 - 2.1300
52 Week Range1.6300 - 8.5000
Volume667,723
Avg. Volume451,890
Market Cap109.652M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-1.9530
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21
    GlobeNewswire

    ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21

    Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of two posters at the ASRM 2020 Virtual Scientific Congress and Expo during the first ever Late-Breaking Abstract Poster Session.Late-breaking poster – P-931: Linzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trialsDr. Linda Bradley, Professor of Ob/Gyn and Reproductive Biology and Vice Chair, Ob/Gyn and Women’s Health Institute, Cleveland Clinic OH, is lead author for a late-breaking poster, which discusses the potential for the low-dose (100 mg) of linzagolix, a once daily oral GnRH antagonist, to fill an unmet need for medical treatment of uterine fibroids in women who cannot or prefer to avoid hormonal add-back therapy (ABT). CDC data suggest that up to 50% of women with uterine fibroids may have a contraindication to ABT. Because linzagolix is the only oral GnRH antagonist being developed with a low-dose, no add-back therapy option, it has the potential to address the unique needs of black women, who are both disproportionately affected with uterine fibroids and are more likely to have contraindications to ABT.Late-breaking poster – P-930: Efficacy and Safety of Linzagolix for the Treatment of Heavy Menstrual Bleeding Due to Uterine Fibroids:  Results from Two Phase 3 Randomized Clinical TrialsThe second late-breaking poster, with lead author Dr. Elizabeth Stewart, Professor of Obstetrics and Gynecology and Chair of the Division of Reproductive Endocrinology, Mayo Clinic MN, presented results from PRIMROSE 1 and PRIMROSE 2, the two positive Phase 3 clinical trials, which support the potential best-in-class efficacy of linzagolix in the treatment of uterine fibroids.The related abstracts are scheduled to be published online in the Fertility and Sterility Abstract Supplement in October 2020.About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer outcomes following in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.About LinzagolixYselty® (linzagolix) is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.Yselty® is a registered trademark owned by Kissei for use by ObsEva. Yselty® is not yet approved for use anywhere in the world. About KisseiKissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia, which is sold worldwide through its licensees. KLH-2109/OBE2109/linzagolix is a new chemical entity discovered by Kissei R&D and currently in development in Japan by Kissei.Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential best-in-class efficacy and therapeutic benefits of linzagolix, including addressing the unique needs of black women. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on August 6, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact: CEO Office Shauna Dillon Shauna.dillon@obseva.ch +41 22 552 1550 Attachment * Press Release in Pdf

  • ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21
    GlobeNewswire

    ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21

    Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of a poster at the ASRM 2020 Virtual Scientific Congress and Expo.Poster number P-482: The Effect of the Oral Oxytocin Antagonist, Nolasiban, On Pregnancy Rates in Women Undergoing Embryo Transfer Following IVFDr. Georg Griesinger, Professor at Luebeck University, Germany, and chair of the Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, is lead author of a poster presenting results from a meta-analysis of the clinical trials and a mechanism of action study of nolasiban, an oxytocin receptor antagonist being developed for its potential to increase pregnancy rates following in vitro fertilization (IVF). Results support the further evaluation of higher doses and/or alternate regimens of nolasiban. ObsEva is partnering with YuYuan BioScience Technology, a Chinese company, for the development of nolasiban.The related abstract is scheduled to be published online in the Fertility and Sterility Abstract Supplement in October 2020.About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer (ET) outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.About Nolasiban Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China).About Assisted Reproductive Technology Infertility affects about 10% of reproductive-aged couples, with more than two million assisted reproductive technology (ART) treatments (including IVF and intracytoplasmic sperm injection (ICSI)) performed worldwide each year. In China, more than 950,000 ART cycles (IVF, ICSI, fetal ET) were performed in 2017 (National Health Commission of the PRC, presented at the 23rd International Federation of Fertility Societies conference in Shanghai, 2019).While the success of ART depends on multiple factors including ovarian response, fertilization, embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and insufficient blood flow to the uterus, may impair the implantation of the embryo.About YuYuan Bioscience TechnologyYuYuan Bioscience Technology is a leading biopharmaceutical company based in China focused on discovering, developing and commercializing innovative medicines for unmet medical needs in the assisted reproductive area. The company continues to introduce a competitive portfolio of therapeutic programs aimed at helping to bring more solutions to this field. YuYuan Bioscience has a top class leadership team with deep experience at assisted reproductive therapeutics and within biotech organizations. The team has a strong track record of success – successfully having taken drug candidates into clinical trials in China, secured regulatory approvals and achieved great market success. YuYuan Bioscience has always adhered to the development concept of “doing moral business, craving long-lasting career”, providing comprehensive, accurate and professional services for China's assisted reproductive medical field.Cautionary Note Regarding Forward Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential of nolasiban to improve pregnancy rates following IVF. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development and related regulatory reviews and approvals, including the risk that the results of earlier clinical trials may not be predictive of the results of later-stage clinical trials, related interactions with regulators, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on August 6, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact: CEO Office contact Shauna Dillon Shauna.dillon@obseva.ch +41 22 552 1550 Attachment * Press Release in Pdf

  • These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright
    TipRanks

    These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright

    Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less than $5 per share, are known for stirring up mixed reactions among market watchers, as these names are unrivaled in terms of both their risk and reward potential.Some argue the bargain prices are just too good to be true, noting that there could be a very legitimate reason they are trading at such low levels. Problems like weak fundamentals or overwhelming headwinds come to mind here.However, the more risk-tolerant see the possibility of colossal returns as too enticing to ignore. With these stocks, you get more bang for your buck. Additionally, given the lower price tags, even minor share price appreciation can translate to massive percentage gains.Taking this into account, we turned to the pros from investment firm H.C. Wainwright for some inspiration. Looking at two penny stocks with the H.C. Wainwright stamp of approval, the firm’s top analysts believe both could quadruple, or more, in the next year.Running the tickers through TipRanks’ database, we wanted to find out what makes both names so compelling even with the risk involved.ObsEva SA (OBSV)Hoping to usher in a new era in women’s reproductive health, ObsEva works to bring the products women need to market. Currently going for $2.5 apiece, H.C. Wainwright thinks that the share price presents an attractive entry point.Representing the firm, 5-star analyst Raghuram Selvaraju points out that pivotal data for linzagolix, the company’s lead candidate, in uterine fibroids appears “best-in-class.” Linzagolix is an orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist that could potentially provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with the currently approved treatment.Looking at the data from the pivotal trials of the therapy, PRIMROSE 1 and PRIMROSE 2, the former met the primary endpoint at 24 weeks, demonstrating that women receiving linzagolix experienced a statistically significant and clinically meaningful reduction in menstrual blood loss compared to placebo. Additionally, patients that received the 200mg dose of linzagolix with add-back therapy (ABT) achieved a 75.5% responder rate and those receiving the 100mg dose of linzagolix without ABT achieved a 56.4% responder rate.As for PRIMROSE-2, longer-term data revealed that continued treatment with linzagolix for 52 weeks provided sustained efficacy, with the drug also well-tolerated. Responder rates of 91.6% and 53.2% were observed in women receiving 200mg with ABT and 100mg without ABT, respectively, both of which are similar to the responder rates observed at week 24 of the study. Weighing in on this result, Selvaraju stated, “This underscores the durability of the efficacy achieved with linzagolix.”Given that both studies saw women receiving linzagolix experience statistically significant improvements across a number of clinically relevant secondary endpoints, including reduction in pain, improvement in anemia and quality of life, Selvaraju has high hopes.“From our vantage point, linzagolix appears to have best-in-class potency among the clinical-stage gonadotropin-releasing hormone (GnRH) receptor antagonists, along with the ability to be deployed without ABT. Thus, we continue to see it as a best-in-class drug,” the analyst opined.On top of this, Selvaraju highlights the Phase 3 EDELWEISS trials evaluating linzagolix, with the data readout set for next year, in endometriosis as another area to watch. “Positive data for relugolix from Myovant Sciences in the SPIRIT Phase 3 trials appear to have reduced the risk profile of linzagolix in treating endometriosis-associated pain. Relugolix met both co-primary endpoints in each of the SPIRIT studies. We remain confident that linzagolix could be an even more effective GnRH receptor antagonist than relugolix, with the added edge of utility without add-back therapy (ABT),” he said.To this end, Selvaraju rates OBSV a Buy along with a $23 price target. Should this target be met, a twelve-month gain of 812% could be in store. (To watch Selvaraju’s track record, click here)Do other analysts agree with Selvaraju? As it turns out, most do. 3 Buy ratings and a single Hold add up to a Strong Buy analyst consensus. At $15.75, the average price target indicates 535% upside potential from current levels. (See ObsEva stock analysis on TipRanks)Galectin Therapeutics (GALT)Using its unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function, Galectin Therapeutics develops new therapies to improve the lives of patients with chronic liver and skin diseases as well as cancer. While H.C. Wainwright says investors need patience when it comes to this name, which changes hands for $2.70 a share, the firm sees it as a long-term winner.On September 29, the company provided more detail on its NASH-RX Phase 2b/3 trial evaluating its galectin-3 inhibitor candidate, belapectin (GR-MD-02), designed for the treatment of NASH cirrhosis patients who have clinical signs of portal hypertension (PH) and are at risk of developing esophageal varices. It should be noted that GALT is one of the few companies with a late clinical stage candidate for NASH cirrhosis, and NASH-RX is the first and only pivotal program for the cirrhotic NASH population.NASH-RX evaluates two belapectin doses versus placebo in about 315 NASH patients in its Phase 2b portion. In addition, following a pre-specified interim analysis (IA) conducted by the trial's Data Monitoring Committee (DMC) when all patients in the Phase 2b portion have completed at least 78 weeks of treatment and underwent a gastroesophageal endoscopic (EGD) assessment, belapectin could either be eligible for accelerated approval if the primary endpoint of reduced incidence of new varices is achieved, or advance into a Phase 3 portion with an optimal belapectin dose enrolling an additional 210 patients.Covering the stock for H.C. Wainwright, 5-star analyst Ed Arce noted: “For the Phase 3 portion, Galectin could choose to implement adaptations including sample size and randomization ratio adjustments, inclusion/exclusion criteria changes, and to incorporate results of a separate hepatic impairment study. Therefore, NASH-RX has two shots on goal for success, with the interim analysis of the Phase 2b portion that is expected in Q2 2023 as its first shot on goal.”When it comes to the available clinical data, top-line results from the Phase 2b NASH-CX study demonstrated a statistically significant and clinically meaningful reduction in the absolute change of the hepatic venous pressure gradient (HVPG) at 54 weeks within a patient subset, without varices at baseline, who were treated with belapectin 2mg/kg. Arce believes it’s encouraging that no patients in this NASH-CX patient subset reported the formation of new varices, compared to 18% of patients in the placebo group.Expounding on this, Arce stated, “We note that patients with no baseline varices represented approximately 50% of the total NASH-CX study population, and is now an entry criteria for the NASH-RX study... While this subset analysis represents a small patient sample size, it nonetheless provides the early clinical rationale to support belapectin's entry into the NASH-RX trial with a specific patient population.” He added, “We continue to believe in belapectin's potential in NASH cirrhosis.”Taking all of this into consideration, Arce maintains a Buy rating and $12 price target. This target conveys his confidence in GALT’s ability to climb 358% higher in the next year. (To watch Arce’s track record, click here)Turning to the rest of the Street, it has been quiet with respect to other analyst activity. As Arce is the only analyst that has thrown an opinion into the mix over the last three months, GALT is a Moderate Buy. (See GALT stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.